Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Saxena, Ajay Kumar
Nayar, Seema A
Pandey, Kailash C
MetadataShow full item record
AbstractThe SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is responsible for the COVID-19 outbreak. The highly contagious COVID-19 disease has spread to 216 countries in less than six months. Though several vaccine candidates are being claimed, an effective vaccine is yet to come. A novel reverse epitomics approach, 'overlapping-epitope-clusters-to-patches' method is utilized to identify the antigenic regions from the SARS-CoV-2 proteome. These antigenic regions are named as 'Ag-Patch or Ag-Patches', for Antigenic Patch or Patches. The identification of Ag-Patches is based on the clusters of overlapping epitopes rising from SARS-CoV-2 proteins. Further, we have utilized the identified Ag-Patches to design Multi-Patch Vaccines (MPVs), proposing a novel method for the vaccine design. The designed MPVs were analyzed for immunologically crucial parameters, physiochemical properties and cDNA constructs. We identified 73 CTL (Cytotoxic T-Lymphocyte) and 49 HTL (Helper T-Lymphocyte) novel Ag-Patches from the proteome of SARS-CoV-2. The identified Ag-Patches utilized to design MPVs cover 768 overlapping epitopes targeting 55 different HLA alleles leading to 99.98% of world human population coverage. The MPVs and Toll-Like Receptor ectodomain complex shows stable complex formation tendency. Further, the cDNA analysis favors high expression of the MPVs constructs in a human cell line. We identified highly immunogenic novel Ag-Patches from the entire proteome of SARS CoV-2 by a novel reverse epitomics approach and utilized them to design MPVs. We conclude that the novel MPVs could be a highly potential novel approach to combat SARS-CoV-2, with greater effectiveness, high specificity and large human population coverage worldwide.
CitationJ Biomol Struct Dyn. 2020 Nov 6:1-20. doi: 10.1080/07391102.2020.1838329. Epub ahead of print.
AffiliationCSSB, Centre for Structural Systembiologie, Notkestr.85, 22607 Hamburg. Germany.
PublisherTaylor & Francis
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.
- Authors: Srivastava S, Verma S, Kamthania M, Kaur R, Badyal RK, Saxena AK, Shin HJ, Kolbe M, Pandey KC
- Issue date: 2020 Jan-Dec
- Design of novel multi-epitope vaccines against severe acute respiratory syndrome validated through multistage molecular interaction and dynamics.
- Authors: Srivastava S, Kamthania M, Kumar Pandey R, Kumar Saxena A, Saxena V, Kumar Singh S, Kumar Sharma R, Sharma N
- Issue date: 2019 Oct
- Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach.
- Authors: Srivastava S, Kamthania M, Singh S, Saxena AK, Sharma N
- Issue date: 2018
- Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
- Authors: Tahir Ul Qamar M, Shahid F, Aslam S, Ashfaq UA, Aslam S, Fatima I, Fareed MM, Zohaib A, Chen LL
- Issue date: 2020 Sep 16
- An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.
- Authors: Yang Z, Bogdan P, Nazarian S
- Issue date: 2021 Feb 5